We have previously published the results of an infliximab (IFX) population PK model in children and young adults with Crohn’s disease (CD). We found that prediction accuracy was improved with less unexplained variability when the five covariates of drug clearance were included. We also developed a clinical decision support tool (RoadMABTM) to promote physician driven model-informed precision dosing. As IFX has a relatively long half-life, it is currently unknown under what conditions (Bayesian posterior) model performance would be improved.